EP3253760A2 - Procédé de synthèse de baricitinib et d'un intermédiaire de celui-ci - Google Patents

Procédé de synthèse de baricitinib et d'un intermédiaire de celui-ci

Info

Publication number
EP3253760A2
EP3253760A2 EP16746200.1A EP16746200A EP3253760A2 EP 3253760 A2 EP3253760 A2 EP 3253760A2 EP 16746200 A EP16746200 A EP 16746200A EP 3253760 A2 EP3253760 A2 EP 3253760A2
Authority
EP
European Patent Office
Prior art keywords
formula
acetonitrile
azetidin
ethylsulfonyl
dioxaborolan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16746200.1A
Other languages
German (de)
English (en)
Other versions
EP3253760A4 (fr
Inventor
Md Abul Kalam AZAD
Gyanendra Pandey
Kaptan Singh
Mohan Prasad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Priority claimed from PCT/IB2016/050529 external-priority patent/WO2016125080A2/fr
Publication of EP3253760A2 publication Critical patent/EP3253760A2/fr
Publication of EP3253760A4 publication Critical patent/EP3253760A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention provides processes for the preparation of baricitinib of Formula I and an intermediate of Formula V.
  • the present invention also provides the of the intermediate of Formula V for the preparation of baricitinib.
  • Baricitinib is a Janus kinase (JAK) inhibitor. It is chemically designated as (ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-lH-pyrazol-l-yl]azetidin-3 yl ⁇ acetonitrile, having the structure as depicted in Formula I.
  • JK Janus kinase
  • U.S. Patent No. 8,158,616 discloses a process for the preparation of baricitinib comprising the reaction of 2-(l-(ethylsulfonyl)azetidin-3-ylidene)acetonitrile of Formula II with 4-(lH-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl methyl pivalate of Formula II
  • the present invention provides an environmentally friendly, cost-effective, and industrially advantageous process for the preparation of baricitinib of Formula I.
  • the process of the present invention involves the use of an environmentally benign heterogeneous catalyst, such as a zeolite.
  • an environmentally benign heterogeneous catalyst such as a zeolite.
  • the use of a zeolite as a catalyst is beneficial for large scale synthesis, owing to its inexpensive nature, ease of handling, ease of isolation of the product, high reaction yields, and recyclability.
  • the process of the present invention involves the use of ⁇ l-(ethylsulfonyl)-3-[4-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-lH-pyrazol-l-yl]azetidin-3-yl ⁇ acetonitrile of Formula V as an intermediate for the preparation of baricitinib of Formula I, which makes the entire process unique.
  • a first aspect of the present invention provides a process for the preparation of baricitinib of Formula I,
  • a second aspect of the present invention provides a process for the preparation of ⁇ l-(emylsulfonyl)-3-[4-(4,4,5,5 etramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-l- yl]azetidin-3-yl ⁇ acetonitrile of Formula V,
  • a third aspect of the present invention provides a process for the preparation of baricitinib of Formula I,
  • a fourth aspect of the present invention provides a compound of Formula V.
  • a fifth aspect of the present invention provides a compound of Formula V
  • ambient temperature refers to a temperature in the range of about 20°C to about 35°C.
  • zeolite refers to natural or modified aluminosilicates, such as montmorillonite K-10 and montmorillonite KSF.
  • solvents to be used for the processes of the present invention include solvents selected from the group consisting of alcohols, hydrocarbons, ethers, chlorinated hydrocarbons, ketones, amides, sulphoxides, water, nitriles, and mixtures thereof.
  • Examples of alcohols include methanol, ethanol, n-propanol, and iso-propanol.
  • hydrocarbons include benzene, toluene, and xylene.
  • Examples of ethers include diethyl ether, ethyl methyl ether, di-isopropyl ether, tetrahydrofuran, and 1,4-dioxane.
  • Examples of chlorinated hydrocarbons include dichloromethane and chloroform.
  • Examples of ketones include acetone, dimethyl ketone, ethyl methyl ketone, and methyl iso-butyl ketone.
  • Examples of amides include N,N-dimethylformamide and N,N- dimethylacetamide.
  • Examples of sulphoxides include dimethyl sulphoxide and diethyl sulphoxide.
  • nitriles include acetonitrile, propionitrile, and benzonitrile.
  • bases to be used for the processes of the present invention include inorganic and organic bases.
  • examples of inorganic bases include alkali and alkaline earth metal hydroxides, carbonates, and bicarbonates.
  • alkali and alkaline earth metal hydroxides include lithium hydroxide, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, and barium hydroxide.
  • alkali and alkaline earth metal carbonates include sodium carbonate, potassium carbonate, calcium carbonate, and magnesium carbonate.
  • alkali and alkaline earth metal bicarbonates include sodium bicarbonate and potassium bicarbonate.
  • organic bases include ⁇ , ⁇ -diisopropylethylamine, triethylamine, triisopropylamine, N,N-2- trimethyl-2-propanamine, N-methylmorpholine, 4-dimethylaminopyridine, 2,6-di-tert- butyl-4-dimethylaminopyridine, l,4-diazabicyclo[2.2.2]octane, and 1,8- diazabicyclo [5.4.0]undec-7-ene .
  • tert-butyl 3-(cyanomethylene)azetidine- 1-carboxylate of Formula VI and the 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole of Formula VIII can be prepared by the process disclosed in U.S. Patent No. 8,158,616.
  • the reaction of the tert-butyl 3 -(cyanomethylidene)azetidine- 1-carboxylate of Formula VI with a zeolite and hydrochloric acid to obtain 3-(cyanomethylene)azetidine hydrochloride of Formula VII is carried out in a solvent.
  • the solvent is selected from the solvents described hereinbefore.
  • the reaction is carried out between ambient temperature and reflux temperature of the solvent for about 5 hours to about 24 hours.
  • the zeolite used is montmorillonite K-10 and the solvent used is methanol.
  • the solvent and base are selected from the solvents and bases described hereinbefore.
  • the reaction is carried out between ambient temperature and the reflux temperature of the solvent for about 5 hours to about 24 hours.
  • the base used is potassium carbonate and the reaction is carried out at ambient temperature for about 16 hours to about 18 hours.
  • tetrakis(triphenylphosphine)palladium(0) is used.
  • the reaction is carried out between ambient temperature and the reflux temperature of the solvent for about 5 hours to about 24 hours. In an embodiment of the present invention, the reaction is carried out at the reflux temperature of the solvent for about 4 hours to about 6 hours.
  • Aqueous hydrochloric acid (6N, 10 mL) and montmorillonite K-10 (2 g) were added into a reaction vessel at ambient temperature. The contents were stirred for 1 hour, and then filtered under reduced pressure to obtain activated montmorillonite K-10.
  • the activated montmorillonite K-10 was added into another reaction vessel containing tert- butyl 3-(cyanomethylidene)azetidine-l-carboxylate (2 g; Formula VI) and methanol (20 mL) at ambient temperature. The reaction mixture was refluxed for about 12 hours to about 15 hours. On completion, the reaction mixture was filtered under reduced pressure followed by recovery of methanol under reduced pressure at about 40°C to about 45°C to obtain 3-(cyanomethylene)azetidine hydrochloride.
  • N,N-Diisopropylethylamine (4.5 mL) was added into a reaction vessel containing acetonitrile (50 mL) and 3-(cyanomethylene)azetidine hydrochloride (1.5 g; Formula VII) at about 0°C to about 10°C. The reaction mixture was stirred for about 10 minutes.
  • Ethanesulfonyl chloride (2.22 g) was added into the reaction mixture at about 0°C to about 5°C over about 5 minutes. The temperature of the reaction mixture was raised to about 20°C to about 25 °C, and then the reaction mixture was stirred for about 16 hours. On completion of the reaction, acetonitrile was recovered from the reaction mixture under reduced pressure at about 40°C to about 45°C to obtain an oily residue. Dichloromethane (50 mL) was added into the residue.
  • 1,4-Dioxane (20 mL) was added into a reaction vessel containing a solution of potassium carbonate (4.5 g) in water (30 mL) at about 20°C to about 25 °C.
  • 2-(l- (Ethylsulfonyl)azetidin-3-ylidene)acetonitrile (2 g; Formula II)
  • 4-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)-lH-pyrazole (2.30 g; Formula VIII) were added into the reaction mixture at about 20°C to about 25 °C.
  • the reaction mixture was stirred at about 20°C to about 25 °C for about 16 hours to about 18 hours.
  • 1,4- dioxane was recovered from the reaction mixture under reduced pressure at about 45 °C to obtain a residue.
  • Ethyl acetate (20 mL) was added into the residue, and the contents were stirred for about 5 minutes.
  • the organic and aqueous layers were separated.
  • the organic layer was concentrated under reduced pressure at about 45 °C to obtain ⁇ l-(ethylsulfonyl)- 3-[4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazol-l-yl]azetidin-3- yl ⁇ acetonitrile.
  • 1,4-dioxane was recovered from the reaction mixture under reduced pressure at about 45°C to obtain a residue.
  • Ethyl acetate 50 mL was added into the residue, and then the contents were stirred for about 5 minutes. The organic and aqueous layers were separated. The organic layer was concentrated under reduced pressure at about 45°C to obtain baricitinib.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des procédés de préparation de baricitinib de Formule I, et un intermédiaire de Formule V. La présente invention concerne également l'utilisation de l'intermédiaire de Formule V pour la préparation de baricitinib.
EP16746200.1A 2015-02-02 2016-02-02 Procédé de synthèse de baricitinib et d'un intermédiaire de celui-ci Withdrawn EP3253760A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN289MU2016 2015-02-02
PCT/IB2016/050529 WO2016125080A2 (fr) 2015-02-02 2016-02-02 Procédé de synthèse de baricitinib et d'un intermédiaire de celui-ci

Publications (2)

Publication Number Publication Date
EP3253760A2 true EP3253760A2 (fr) 2017-12-13
EP3253760A4 EP3253760A4 (fr) 2018-06-20

Family

ID=60239701

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16746200.1A Withdrawn EP3253760A4 (fr) 2015-02-02 2016-02-02 Procédé de synthèse de baricitinib et d'un intermédiaire de celui-ci

Country Status (1)

Country Link
EP (1) EP3253760A4 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020072870A1 (fr) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Formes co-cristallines du baricitinib

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI444382B (zh) * 2008-03-11 2014-07-11 Incyte Corp 作為ｊａｋ抑制劑之氮雜環丁烷及環丁烷衍生物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020072870A1 (fr) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Formes co-cristallines du baricitinib

Also Published As

Publication number Publication date
EP3253760A4 (fr) 2018-06-20

Similar Documents

Publication Publication Date Title
WO2016125080A2 (fr) Procédé de synthèse de baricitinib et d'un intermédiaire de celui-ci
JP5656837B2 (ja) ［１Ｓ−［１α，２α，３β（１Ｓ＊，２Ｒ＊），５β］］−３−［７−［２−（３，４−ジフルオロフェニル）−シクロプロピルアミノ］−５−（プロピルチオ）−３Ｈ−１，２，３−トリアゾロ［４，５−ｄ］ピリミジン−３−イル］−５−（２−ヒドロキシエトキシ）シクロペンタン−１，２−ジオールおよびその中間体の製造方法
US9873706B2 (en) Process for the preparation of baricitinib and an intermediate thereof
EP2970300B1 (fr) Composés hétéroaromatiques en tant qu'inhibiteurs btk
TW201038575A (en) Processes for preparing JAK inhibitors and related intermediate compounds
EP2970163B1 (fr) Dérivés de 5-thiazolecarboxamide et leur utilisation en tant qu'inhibiteurs de la btk
KR20180008637A (ko) ｛1-(에틸술포닐)-3-[4-(7H-피롤로[2,3-d]피리미딘-4-일)-1H-피라졸-1-일]아제티딘-3-일｝아세토니트릴의 제조를 위한 방법 및 중간체
CN101300237A (zh) 制备用作氟苯尼考中间体的唑烷保护的氨基二醇化合物的方法
WO2016030704A1 (fr) Forme solide d'intermédiaire de ticagrelor
AU2018366342A1 (en) Method for preparing Baricitinib
CN104520278A (zh) 三唑并嘧啶碳核苷的中间体的制备方法
JP4518422B2 (ja) Ｏｈ−保護された［４−（２，６−ジアミノ−９ｈ−プリン−９−イル）−１，３−ジオキソラン−２−イル］メタノール−誘導体の製法
KR102477924B1 (ko) 인돌 카르복스아미드 화합물을 제조하는 방법
KR20230005928A (ko) Iap 길항제 화합물 및 중간체 및 이를 합성하는 방법
EP3253760A2 (fr) Procédé de synthèse de baricitinib et d'un intermédiaire de celui-ci
US9453001B2 (en) Avanafil preparation method
CN105418612B (zh) 一种多索茶碱的制备方法
US9604991B2 (en) Preparation method of ticagrelor and intermediates thereof
CN104987325B (zh) 一种伏立康唑的制备方法
AU2013345930A1 (en) 2-pyridone compound
JPH07504178A (ja) アンギオテンシン２レセプター拮抗剤としてのトリアゾロピリミジン誘導体
CN104411687A (zh) 一种用于制备索非那新或其盐的方法
CN102675220B (zh) 一种制备依曲韦林的方法及其中间体
KR20170035917A (ko) 피리미딘-1-올 화합물의 제조 방법, 및 이의 중간체
KR102011648B1 (ko) 1-알킬-3-디플루오르메틸-5-히드록시피라졸의 제조 방법

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170904

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180523

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 487/04 20060101AFI20180516BHEP

Ipc: A61K 31/4353 20060101ALI20180516BHEP

Ipc: A61K 31/397 20060101ALI20180516BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190314

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190525